- Poster presentation
- Open Access
Switch from enfuvirtide (ENF) to raltegravir (RAL): a simplification option for heavily pretreated HIV patients (pts)
© Gatti et al; licensee BioMed Central Ltd. 2008
- Published: 10 November 2008
- Access Programme
ENF was the first HIV entry-inhibitor approved by the FDA in 2003, which offered hope to many pretreated pts on a failing antiretroviral (ARV) regimen; but ENF is difficult to take since it requires reconstitution, parenteral administration and it causes local reactions at injection sites. Raltegravir (RAL) is the first commercially available HIV-integrase inhibitor; BENCHMARK 1–2 studies demonstrated its efficacy in treatment-experienced pts harbouring multiresistant HIV strains especially when associated with ENF in ENF-naïve pts. The aim of this analysis was to longitudinally evaluate the viro-immunological and safety outcome of experienced patients switching from ENF to RAL in order to simplify the treatment schedule which may be often very complicated in 'salvage' therapy.
Pts were enrolled during the expanded access programme of RAL in the outpatient HIV clinic of Brescia. Viral load (VL, bDNA), CD4 cell count, AST, ALT, total cholesterol (TC), tryglicerides (TG) and glycemia were recorded at baseline (BL) and every 3 months (T3, T6); results are expressed as median (range); parametric and non-parametric tests have been used for comparison of continuous variables between groups when appropriate (p < 0.05 considered significant).
BL (n = 15)
T3 (n = 15)
T6 (n = 11)
CD4 cell count (cells/mL)
The switch from ENF to RAL was efficacious and well tolerated in a small cohort of heavily pretreated HIV pts; this ARV change may represent a sort of 'simplification' option for multiresistant pts taking ENF with at least another active drug in the regimen.
This article is published under license to BioMed Central Ltd.